# Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

> **NCT01708902** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 876 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** linagliptin2.5mg/metformin1000mg
- **DRUG:** linagliptin2.5mg/metformin1000mg
- **DRUG:** linagliptin 5mg
- **DRUG:** Metformin 500mg
- **DRUG:** linagliptin2.5mg/metformin500mg
- **DRUG:** linagliptin2.5mg/metformin500mg
- **DRUG:** linagliptin 5mg
- **DRUG:** Metformin 1000mg

## Key facts

- **NCT ID:** NCT01708902
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 876 (ACTUAL)
- **Last updated:** 2015-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01708902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01708902, "Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01708902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*